Predictable clinical effects in the treatment of hypertension and chronic, stable angina pectoris: Clinical studies of mibefradil

Journal of Hypertension, Supplement

Volumn 15, Issue 3, 1997, Pages

  Kobrin, Isaac ^a   Charlon, Vincent ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

Angina pectoris; Hypertension; Mibefradil

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; MIBEFRADIL;

ANGINA PECTORIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; DRUG TOLERABILITY; HEART RATE; HUMAN; HYPERTENSION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASODILATATION;

EID: 0030937296     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Kannel W: Blood pressure as a cardiovascular risk factor: prevention and treatment JAMA 1996, 275:1571-1576.
2. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 1970, 213:1143-1152.
3. Burt VL, Whelton P, Roccella E, Brown C, Cutter JA, Higgins M, et al.: Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey. Hypertension 1995, 25:305-313.
4. Jones JK, Gorkin L, Lian JF, Staffa J, Fletchet AP: Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of United Kingdom population. BMJ 1995, 311:293-295.
5. Luepter R: Stroke deaths reverse 20-year decline. In Report to the American Heart Association Annual Science Writers Forum. Santa Barbara, California: American heart Association; 1995.
6. 2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol 1989, 13:754-759.
7. 2+ channel in cardiac tissue. Eur J Pharmacol 1995, 290:155-158.
8. 2+ channels by Ro 40-5967. Circ Res 1994, 75:144-148.
9. Katz AM: Calcium channel diversity in the cardiovascular system. J Am Coll Cardiol 1996, 28:522-29.
10. Véniant M, Clozel JP, Heudes D, Banken L, Ménard J: Effects of Ro 40-5967, a new calcium antagonist, and enalapril on cardiac remodeling in renal hypertensive rats. J Cardiovasc Pharmacol 1993, 21:544-51.
11. Bogdanov K, Zimar B, Spurgeon H, Lakalla E: L- and T-type calcium currents differ in finch and rat ventricular cardiomyocytes. J Mol Cell Cardiol 1995, 27:2581-2593.
12. Orito K, Satoh K, Taira N: Cardiovascular profile of Ro 40-5967, a new nondihydropyridine calcium antagonist, delineated in isolated, blood-perfused dog hearts. J Cardiovasc Pharmacol 1993, 22:293-299.
13. Schmitt R, Kleinbloesem C, Belz G, Schroeter V, Feifel U, Pozenel H, et al.: Hemodynamic and humoral effect of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther 1992, 52: 314-323.
14. Welker H, Eggers H, Kleinbloesem C, Erb K, Breithaupt K, Butzer R, et al.: RO 40-5967: pharmacokinetics of a new calcium antagonist [abstract]. Eur J Clin Pharmacol 1989, 36 (suppl):A304.
15. Clozel J-P, Osterreider W, Kleinbloesem C, Welker HA, Schlappi B, Tudor R, et al.: Ro 40-5967: a new non-dihydropyridine calcium antagonist Cardiovasc Drug Rev 1991, 9:4-17.
16. Bernink P, Prager G, Schelling A, Kobrin I: Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Hypertension 1996, 27:426-432.
17. Lacourciere Y, Poirier L, Lefebvre J, Archambault F, Dalle Ave S, Ward C, et al.: The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS In moderate to severe hypertensives with ambulatory hypertension. Am J Hypertens 1997 (in press).
18. Bakx AL, van der Wall EE, Braun S, Emanuelsson H, Bruschke AV, Kobrin I: Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Am Heart J 1995, 130:748-757.
19. Braun S, van der Wall EE, Emanuelsson H, Kobrin I: Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. J Am Coll Cardiol 1996, 27:317-322.
20. Pepine JC, Cohn PF, Deedwania PC, Gibson RS, Handberg E, Hill JA, et al.: Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life: the Atenolol Silent Ischemia Study Group (ASIST). Circulation 1994, 90:762-768.
21. Gillum RF, Makuc DM, Feldman JJ: Pulse rate, coronary heart disease and death: the NHANES I epidemiologic follow-up study. Am Heart J 1991, 121:172-177.
22. Thaulow E, Erikssen JE: How important is heart rate? J Hypertens 1991, 9 (suppl 7):S27-S30.
23. Dyer AR, Persky V, Stamler J, Oglesby P, Shekelle RB, Berkson DM, et al.: Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 1980, 112:736-749.
24. Perski A, Olsson G, Landou C, deFaire U, Theorell T, Hamsten A: Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J 1992, 123:609-619.